Skip to content
Search

Latest Stories

Oxford scientists develop five-minute virus test

Scientists from the University of Oxford have developed a rapid Covid-19 test able to identify the coronavirus in less than five minutes, researchers said on Thursday (Oct 15), adding it could be used in mass testing at airports and businesses.

The university said it hoped to start product development of the testing device in early 2021 and have an approved device available six months afterwards.


The device is able to detect the coronavirus and distinguish it from other viruses with high accuracy, the researchers said in a pre-print study.

“Our method quickly detects intact virus particles,” said Professor Achilles Kapanidis, at Oxford’s Department of Physics, adding that this meant the test would be “simple, extremely rapid, and cost-effective”.

Rapid antigen tests are seen as key in rolling out mass-testing and re-opening economies while the coronavirus is still circulating, and those that are already in use are faster and cheaper but less accurate than existing molecular PCR tests.

Siemens Healthineers on Wednesday announced the launch of a rapid antigen test kit in Europe to detect coronavirus infections, but warned that the industry may struggle to meet a surge in demand.

Although the Oxford platform will only be ready next year, the tests could help manage the pandemic in time for next winter. Health officials have warned that the world will need to live with coronavirus even if a vaccine is developed.

“A significant concern for the upcoming winter months is the unpredictable effects of co-circulation of SARS-CoV-2 with other seasonal respiratory viruses,” said Dr Nicole Robb, of Warwick Medical School.

“We have shown that our assay (test) can reliably distinguish between different viruses in clinical samples, a development that offers a crucial advantage in the next phase of the pandemic.”

More For You

Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less